(Q37760062)

22 August 2017

1 reference

title

Neurological adverse events associated with anti-tumor necrosis factor α treatment (English)

1 reference

22 August 2017

Antonio G Tristano

1

1 reference

22 August 2017

publication date

22 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

257

1 reference

22 August 2017

issue

9

1 reference

22 August 2017

page(s)

1421-1431

1 reference

Tumor necrosis factor-alpha antagonists and neuropathy

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5591-7

Adverse cutaneous reactions induced by TNF-alpha antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5591-7

Invited review: cytokine regulation of fever: studies using gene knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5591-7

Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5591-7

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5591-7

Onset of multiple sclerosis associated with anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5591-7

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

12 December 2020

Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy

1 reference

12 December 2020

Demyelination and inhibition of tumor necrosis factor (TNF).

1 reference

12 December 2020

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

1 reference

12 December 2020

TNF receptor subtype signalling: differences and cellular consequences

1 reference

12 December 2020

Distal lower extremity paresthesia and foot drop developing during adalimumab therapy

1 reference

12 December 2020

The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

1 reference

12 December 2020

Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue

1 reference

12 December 2020

Etanercept and demyelinating disease in a patient with psoriasis

1 reference

12 December 2020

Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers

1 reference

12 December 2020

Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy

1 reference

12 December 2020

TNF alpha and the TNF receptor superfamily: structure-function relationship(s).

1 reference

12 December 2020

Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barré syndrome

1 reference

12 December 2020

Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

1 reference

12 December 2020

Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection

1 reference

12 December 2020

Control of synaptic strength by glial TNFalpha

1 reference

12 December 2020

Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site

1 reference

12 December 2020

TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition

1 reference

12 December 2020

Multifocal motor neuropathy during treatment with infliximab

1 reference

12 December 2020

Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy

1 reference

12 December 2020

TNF signaling: early events and phosphorylation.

1 reference

12 December 2020

Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy

1 reference

12 December 2020

Continuous autotropic signaling by membrane-expressed tumor necrosis factor

1 reference

12 December 2020

Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy

1 reference

12 December 2020

Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus

1 reference

12 December 2020

A population-based study of multiple sclerosis in twins: update

1 reference

12 December 2020

New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients

1 reference

12 December 2020

Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system

1 reference

12 December 2020

Tumor necrosis factor-alpha in peripheral nerve lesions

1 reference

12 December 2020

Neurological complications of infliximab

1 reference

12 December 2020

[Cytokines and peripheral neuropathies]

1 reference

12 December 2020

Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis?

1 reference

12 December 2020

Elevation of tumor necrosis factor in head injury

1 reference

12 December 2020

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy

1 reference

12 December 2020

Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic

1 reference

12 December 2020

Induction of apoptosis in mature T cells by tumour necrosis factor

1 reference

12 December 2020

Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy

1 reference

12 December 2020

Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome

1 reference

12 December 2020

Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy

1 reference

12 December 2020

Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor

1 reference

12 December 2020

Tumour necrosis factor and cancer

1 reference

12 December 2020

Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease

1 reference

12 December 2020

Safety of tumour necrosis factor-alpha antagonists

1 reference

12 December 2020

Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome

1 reference

12 December 2020

Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease

1 reference

12 December 2020

Effects of Interleukin-1 and Tumor Necrosis Factor-α on Astrocytes, Microglia, Oligodendrocytes, and Glial Precursors in vitro

1 reference

12 December 2020

Involvement of tumor necrosis factor alpha in hippocampal development and function.

1 reference

12 December 2020

Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system

1 reference

12 December 2020

Differential TNF-signaling in chronic inflammatory disorders

1 reference

12 December 2020

Etanercept in rheumatoid arthritis

1 reference

12 December 2020

The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire

1 reference

12 December 2020

Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis

1 reference

12 December 2020

A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'

1 reference

12 December 2020

Tumor necrosis factor identified in multiple sclerosis brain

1 reference

12 December 2020

Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment

1 reference

12 December 2020

TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex

1 reference

12 December 2020

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

1 reference

12 December 2020

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

12 December 2020

Glutamate neurotoxicity and diseases of the nervous system

1 reference

12 December 2020

Demyelinating events in rheumatoid arthritis after drug exposures

1 reference

12 December 2020

TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease

1 reference

12 December 2020

Nerve lesions induced by macrophage activation

1 reference

12 December 2020

Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis

1 reference

12 December 2020

Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-alpha

1 reference

12 December 2020

Tumor necrosis factor and motoneuronal degeneration: an open problem.

1 reference

12 December 2020

Multiple sclerosis and chronic inflammatory diseases. A case-control study

1 reference

12 December 2020

Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells

1 reference

12 December 2020

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

1 reference

12 December 2020

Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro

1 reference

12 December 2020

Autoimmune diseases induced by biological agents: a double-edged sword?

1 reference

12 December 2020

Tumor necrosis factor: a master-regulator of leukocyte movement

1 reference

12 December 2020

Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis

1 reference

12 December 2020

Optic neuritis occurring with anti-tumour necrosis factor alpha therapy

1 reference

12 December 2020

Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling

1 reference

12 December 2020

Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death

1 reference

12 December 2020

LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway

1 reference

12 December 2020

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?

1 reference

12 December 2020

The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor

1 reference

12 December 2020

Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis

1 reference

12 December 2020

TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview

1 reference

12 December 2020

Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark

1 reference

12 December 2020

Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF.

1 reference

12 December 2020

Demyelination-like syndrome in Crohn's disease after infliximab therapy

1 reference

12 December 2020

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

1 reference

12 December 2020

Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report

1 reference

12 December 2020

10.1007/S00415-010-5591-7

Identifiers

DOI

1 reference

22 August 2017

1 reference